A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

A prognostic index model was developed, composed of six routinely available and readily assessable factors and categorizing patients with metastatic castration-resistant prostate cancer treated with abiraterone-prednisone into distinct prognostic risk groups. This model could be useful for determining patient prognosis for the purposes of follow-up and monitoring, and may aid in patient stratification for clinical trials.

from Cancer via ola Kala on Inoreader http://ift.tt/1Idxogj
via IFTTT